-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson Announces A More Than $1B Investment In A Next Generation Cell Therapy Manufacturing Facility In Montgomery County, Pennsylvania; Facility To Create More Than 4,000 Construction Jobs & 500 Biomanufacturing Jobs

Benzinga·02/18/2026 15:17:49
Listen to the news
  • Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company's portfolio of transformational medicines
  • Facility will boost Pennsylvania's economy by creating more than 4,000 construction jobs and 500 biomanufacturing jobs, while further strengthening the Company's annual $10 billion economic impact across the state
  • Investment is part of Company's $55 billion U.S. investment by early 2029 and supports plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S.

 

 

Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company's U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.